×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Icosavax Inc. (ICVX) NASDAQ

$15.31 (0.14) (-0.91%)

Market Cap: -

As of 02/16/24 04:00 PM EST. Market closed.

(ICVX)

Icosavax Inc. (ICVX)
NASDAQ

$15.31
(0.14) (-0.91%)

Market Cap: -

As of 02/16/24 04:00 PM EST. Market closed.

Add to Portfolio

icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. the company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the institute for protein design at the university of washington. ... read more

COMPANY PROFILE
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
Address
.
PRICE CHART FOR ICOSAVAX INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$15.45
Days Range
- - -
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
50,090,341
Open
-
Previous Close
$15.45
Days Range
- - -
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
50,090,341
FINANCIAL STATEMENTS FOR ICOSAVAX INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR ICOSAVAX INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Simpson Adam K.Chief Executive OfficerFeb 01, 2024 Option Exercise$1.0415,00015,600373,657Feb 02, 2024, 07:03 PM
Simpson Adam K.Chief Executive OfficerFeb 01, 2024 Sale$15.2915,000229,386358,657Feb 02, 2024, 07:03 PM
Simpson Adam K.Chief Executive OfficerJan 22, 2024 Option Exercise$1.0398,016100,979358,657Jan 23, 2024, 06:15 PM
Kanesa-thasan NiranjanChief Medical OfficerJan 04, 2023 Option Exercise$2.34106,373249,298330,353Jan 05, 2024, 07:18 PM
Kanesa-thasan NiranjanChief Medical OfficerJan 04, 2023 Sale$15.70106,3731,670,460223,980Jan 05, 2024, 07:18 PM
Simpson Adam K.Chief Executive OfficerJan 02, 2024 Option Exercise$1.0415,00015,600275,641Jan 04, 2024, 05:05 PM
Simpson Adam K.Chief Executive OfficerJan 02, 2024 Sale$15.6715,000235,087260,641Jan 04, 2024, 05:05 PM
Simpson Adam K.Chief Executive OfficerDec 21, 2023 Option Exercise$1.36165,917225,085350,641Dec 22, 2023, 06:27 PM
Simpson Adam K.Chief Executive OfficerDec 21, 2023 Sale$15.4490,0001,389,280300,641Dec 22, 2023, 06:27 PM
Simpson Adam K.Chief Executive OfficerDec 20, 2023 Sale$15.4662,205961,509184,724Dec 22, 2023, 06:27 PM
Russo Thomas JosephChief Financial OfficerDec 20, 2023 Sale$15.4615,183234,72042,467Dec 22, 2023, 06:26 PM
Kanesa-thasan NiranjanChief Medical OfficerDec 20, 2023 Sale$15.4611,884183,692223,980Dec 22, 2023, 06:25 PM
Cearley CassiaChief Business OfficerDec 20, 2023 Sale$15.467,934122,637130,694Dec 22, 2023, 06:24 PM
Cearley CassiaChief Business OfficerDec 13, 2023 Sale$16.018,759140,190131,200Dec 15, 2023, 07:35 PM
Simpson Adam K.Chief Executive OfficerAug 01, 2023 Option Exercise$0.843,0002,520246,930Aug 01, 2023, 08:54 PM
Kanesa-thasan NiranjanChief Medical OfficerJul 31, 2023 Sale$8.863,32329,447235,864Aug 01, 2023, 08:32 PM
Simpson Adam K.Chief Executive OfficerJul 31, 2023 Sale$8.8611,788104,459243,930Aug 01, 2023, 08:30 PM
Russo Thomas JosephChief Financial OfficerJul 31, 2023 Sale$8.863,06627,16945,620Aug 01, 2023, 08:28 PM
Cearley CassiaChief Business OfficerJul 31, 2023 Sale$8.861,88816,731139,959Aug 01, 2023, 08:24 PM
Holtzman DouglasChief Scientific OfficerJul 03, 2023 Option Exercise$1.0416,35617,010306,410Jul 03, 2023, 07:43 PM
Holtzman DouglasChief Scientific OfficerJul 03, 2023 Sale$8.8516,356144,743292,149Jul 03, 2023, 07:43 PM
Cearley CassiaChief Business OfficerMay 23, 2023 Sale$10.0010,000100,000141,847May 25, 2023, 07:39 PM
Holtzman DouglasChief Scientific OfficerApr 03, 2023 Option Exercise$1.0420,44321,261310,497Apr 05, 2023, 07:12 PM
Holtzman DouglasChief Scientific OfficerApr 03, 2023 Sale$6.0920,443124,407290,354Apr 05, 2023, 07:12 PM
Cearley CassiaChief Business OfficerMar 06, 2023 Sale$7.755,00038,737151,847Mar 08, 2023, 05:45 PM
Simpson Adam K.Chief Executive OfficerFeb 15, 2023 Option Exercise$1.0410,67711,104255,718Feb 16, 2023, 08:00 PM
Bekiroglu ElizabethGeneral Counsel & Corp. Sec.Feb 13, 2023 Sale$10.695,92263,322103,007Feb 15, 2023, 08:12 PM
Simpson Adam K.Chief Executive OfficerFeb 13, 2023 Sale$10.697,50680,259245,041Feb 15, 2023, 08:09 PM
Holtzman DouglasChief Scientific OfficerFeb 13, 2023 Sale$10.691,52216,274293,403Feb 15, 2023, 08:07 PM
Holtzman DouglasChief Scientific OfficerFeb 14, 2023 Sale$10.173,34934,064290,054Feb 15, 2023, 08:07 PM
Russo Thomas JosephChief Financial OfficerFeb 13, 2023 Sale$10.691,90220,33748,686Feb 15, 2023, 08:04 PM
Kanesa-thasan NiranjanChief Medical OfficerFeb 13, 2023 Sale$10.691,79419,183239,187Feb 15, 2023, 07:58 PM
Cearley CassiaChief Business OfficerFeb 13, 2023 Sale$10.691,66017,750156,847Feb 15, 2023, 07:56 PM
Cearley CassiaChief Business OfficerJan 30, 2023 Option Exercise$0.8425,10221,086156,840Jan 31, 2023, 04:19 PM
Simpson Adam K.Chief Executive OfficerJan 25, 2023 Option Exercise$1.0013,07313,117252,547Jan 27, 2023, 05:02 PM
Simpson Adam K.Chief Executive OfficerDec 23, 2022 Option Exercise$0.8414,36912,070239,474Dec 23, 2022, 07:00 PM
Simpson Adam K.Chief Executive OfficerDec 21, 2022 Sale$8.9666,764598,406225,105Dec 23, 2022, 07:00 PM
Holtzman DouglasChief Scientific OfficerDec 15, 2022 Sale$11.1419,648218,9632,792Dec 16, 2022, 06:36 PM
Bekiroglu ElizabethGeneral Counsel & Corp. Sec.Sep 08, 2022 Sale$4.871,8138,835108,929Sep 09, 2022, 06:44 PM
Simpson Adam K.Chief Executive OfficerAug 02, 2022 Sale$6.701,90412,764291,869Aug 02, 2022, 09:47 PM
Simpson Adam K.Chief Executive OfficerAug 01, 2022 Sale$6.647,01746,575293,772Aug 02, 2022, 09:47 PM
Simpson Adam K.Chief Executive OfficerJul 29, 2022 Sale$7.112,45617,456300,789Aug 02, 2022, 09:47 PM
Russo Thomas JosephChief Financial OfficerAug 01, 2022 Sale$6.641,82512,11349,416Aug 02, 2022, 09:43 PM
Russo Thomas JosephChief Financial OfficerJul 29, 2022 Sale$7.116394,54251,241Aug 02, 2022, 09:43 PM
Russo Thomas JosephChief Financial OfficerAug 02, 2022 Sale$6.704953,31848,921Aug 02, 2022, 09:43 PM
Holtzman DouglasChief Scientific OfficerAug 02, 2022 Sale$6.704533,037293,258Aug 02, 2022, 09:42 PM
Holtzman DouglasChief Scientific OfficerAug 01, 2022 Sale$6.649,33761,973293,711Aug 02, 2022, 09:42 PM
Holtzman DouglasChief Scientific OfficerJul 29, 2022 Sale$7.115854,158303,048Aug 02, 2022, 09:42 PM
Richardson Charles ESVP, Technical OperationsAug 02, 2022 Sale$6.703712,487165,168Aug 02, 2022, 09:40 PM
Richardson Charles ESVP, Technical OperationsAug 01, 2022 Sale$6.641,3689,080165,539Aug 02, 2022, 09:40 PM
Richardson Charles ESVP, Technical OperationsJul 29, 2022 Sale$7.114793,405166,907Aug 02, 2022, 09:40 PM
Kanesa-thasan NiranjanChief Medical OfficerAug 01, 2022 Sale$6.642,00113,281239,857Aug 02, 2022, 09:37 PM
Kanesa-thasan NiranjanChief Medical OfficerJul 29, 2022 Sale$7.117014,982241,858Aug 02, 2022, 09:37 PM
Kanesa-thasan NiranjanChief Medical OfficerAug 02, 2022 Sale$6.705433,640239,314Aug 02, 2022, 09:37 PM
Cearley CassiaChief Business OfficerAug 01, 2022 Sale$6.641,1187,421132,041Aug 02, 2022, 09:34 PM
Cearley CassiaChief Business OfficerJul 29, 2022 Sale$7.113912,779133,159Aug 02, 2022, 09:34 PM
Cearley CassiaChief Business OfficerAug 02, 2022 Sale$6.703032,031131,738Aug 02, 2022, 09:34 PM
Simpson Adam K.Chief Executive OfficerJul 01, 2022 Option Exercise$0.847,1856,035303,245Jul 06, 2022, 06:53 PM
MCDADE MARKDirectorApr 01, 2022 Buy$7.1042,225299,79750,243Apr 05, 2022, 04:10 PM
Simpson Adam K.Chief Executive OfficerMar 28, 2022 Option Exercise$0.844,7894,023220,482Mar 30, 2022, 06:42 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 29, 2022 Buy$4.758,90042,2715,963,565Mar 30, 2022, 04:31 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 28, 2022 Buy$4.53175,318794,6115,953,665Mar 30, 2022, 04:31 PM
Cearley CassiaChief Business OfficerMar 18, 2022 Option Exercise$0.8435,13729,515133,550Mar 22, 2022, 04:36 PM
Cearley CassiaChief Business OfficerMar 07, 2022 Sale$17.1610,000171,62998,897Mar 09, 2022, 05:34 PM
Richardson Charles ESVP, Technical OperationsFeb 14, 2022 Option Exercise$0.8672,56162,188167,386Feb 16, 2022, 05:22 PM
Kanesa-thasan NiranjanChief Medical OfficerFeb 02, 2022 Option Exercise$0.9952,75252,101221,408Feb 04, 2022, 06:25 PM
Simpson Adam K.Chief Executive OfficerJan 26, 2022 Option Exercise$1.0090,69390,968215,693Jan 28, 2022, 06:04 PM
Cearley CassiaChief Business OfficerNov 15, 2021 Option Exercise$0.8322,59818,75685,491Nov 17, 2021, 05:13 PM
NanoDimension III, L.P.Former 10% OwnerAug 02, 2021 Buy$15.00133,3342,000,0102,883,329Aug 04, 2021, 06:20 PM
RA CAPITAL MANAGEMENT, L.P.DirectorAug 02, 2021 Buy$15.002,666,66639,999,9905,140,679Aug 04, 2021, 04:31 PM
Gould Terry PDirectorAug 02, 2021 Buy$15.00133,3342,000,010996,169Aug 03, 2021, 06:56 PM
ADAMS STREET PARTNERS LLCFormer 10% OwnerAug 02, 2021 Buy$15.00133,3342,000,010996,169Aug 03, 2021, 06:24 PM
Richardson Charles ESee RemarksJul 30, 2021 Option Exercise$15.0027,750416,25078,883Aug 02, 2021, 09:32 PM
Cearley CassiaChief Business OfficerJul 30, 2021 Option Exercise$15.0027,750416,25062,893Aug 02, 2021, 09:29 PM
Veneman Ann MDirectorJul 30, 2021 Option Exercise$15.008,500127,5008,500Aug 02, 2021, 09:27 PM
Qiming U.S. Healthcare Fund II, L.P.Former 10% OwnerAug 02, 2021 Buy$15.00221,3513,320,2653,523,561Aug 02, 2021, 09:27 PM
Holtzman DouglasChief Scientific OfficerJul 30, 2021 Option Exercise$15.0041,500622,500282,482Aug 02, 2021, 09:26 PM
FIELDS HEIDIDirectorJul 30, 2021 Option Exercise$15.008,750131,2508,750Aug 02, 2021, 09:25 PM
Simpson Adam K.Chief Executive OfficerJul 30, 2021 Option Exercise$15.00125,0001,875,000125,000Aug 02, 2021, 09:23 PM
Kanesa-thasan NiranjanChief Medical OfficerJul 30, 2021 Option Exercise$15.0041,500622,500168,656Aug 02, 2021, 09:20 PM
Kanesa-thasan NiranjanChief Medical OfficerAug 02, 2021 Buy$15.006,66699,9906,666Aug 02, 2021, 09:20 PM
Russo Thomas JosephChief Financial OfficerJul 30, 2021 Option Exercise$15.0032,500487,50032,500Aug 02, 2021, 09:19 PM
Sanofi10% OwnerAug 02, 2021 Buy$15.0066,6671,000,0053,155,169Aug 02, 2021, 08:34 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Simpson Adam K.Chief Executive Officer02/01/202415,600
Simpson Adam K.Chief Executive Officer02/01/2024229,386
Simpson Adam K.Chief Executive Officer01/22/2024100,979
Kanesa-thasan NiranjanChief Medical Officer01/04/2023249,298
Kanesa-thasan NiranjanChief Medical Officer01/04/20231,670,460
Simpson Adam K.Chief Executive Officer01/02/202415,600
Simpson Adam K.Chief Executive Officer01/02/2024235,087
Simpson Adam K.Chief Executive Officer12/21/2023225,085
Simpson Adam K.Chief Executive Officer12/21/20231,389,280
Simpson Adam K.Chief Executive Officer12/20/2023961,509
Russo Thomas JosephChief Financial Officer12/20/2023234,720
Kanesa-thasan NiranjanChief Medical Officer12/20/2023183,692
Cearley CassiaChief Business Officer12/20/2023122,637
Cearley CassiaChief Business Officer12/13/2023140,190
Simpson Adam K.Chief Executive Officer08/01/20232,520
Kanesa-thasan NiranjanChief Medical Officer07/31/202329,447
Simpson Adam K.Chief Executive Officer07/31/2023104,459
Russo Thomas JosephChief Financial Officer07/31/202327,169
Cearley CassiaChief Business Officer07/31/202316,731
Holtzman DouglasChief Scientific Officer07/03/202317,010
Holtzman DouglasChief Scientific Officer07/03/2023144,743
Cearley CassiaChief Business Officer05/23/2023100,000
Holtzman DouglasChief Scientific Officer04/03/202321,261
Holtzman DouglasChief Scientific Officer04/03/2023124,407
Cearley CassiaChief Business Officer03/06/202338,737
Simpson Adam K.Chief Executive Officer02/15/202311,104
Bekiroglu ElizabethGeneral Counsel & Corp. Sec.02/13/202363,322
Simpson Adam K.Chief Executive Officer02/13/202380,259
Holtzman DouglasChief Scientific Officer02/13/202316,274
Holtzman DouglasChief Scientific Officer02/14/202334,064
Russo Thomas JosephChief Financial Officer02/13/202320,337
Kanesa-thasan NiranjanChief Medical Officer02/13/202319,183
Cearley CassiaChief Business Officer02/13/202317,750
Cearley CassiaChief Business Officer01/30/202321,086
Simpson Adam K.Chief Executive Officer01/25/202313,117
Simpson Adam K.Chief Executive Officer12/23/202212,070
Simpson Adam K.Chief Executive Officer12/21/2022598,406
Holtzman DouglasChief Scientific Officer12/15/2022218,963
Bekiroglu ElizabethGeneral Counsel & Corp. Sec.09/08/20228,835
Simpson Adam K.Chief Executive Officer08/02/202212,764
Simpson Adam K.Chief Executive Officer08/01/202246,575
Simpson Adam K.Chief Executive Officer07/29/202217,456
Russo Thomas JosephChief Financial Officer08/01/202212,113
Russo Thomas JosephChief Financial Officer07/29/20224,542
Russo Thomas JosephChief Financial Officer08/02/20223,318
Holtzman DouglasChief Scientific Officer08/02/20223,037
Holtzman DouglasChief Scientific Officer08/01/202261,973
Holtzman DouglasChief Scientific Officer07/29/20224,158
Richardson Charles ESVP, Technical Operations08/02/20222,487
Richardson Charles ESVP, Technical Operations08/01/20229,080
Richardson Charles ESVP, Technical Operations07/29/20223,405
Kanesa-thasan NiranjanChief Medical Officer08/01/202213,281
Kanesa-thasan NiranjanChief Medical Officer07/29/20224,982
Kanesa-thasan NiranjanChief Medical Officer08/02/20223,640
Cearley CassiaChief Business Officer08/01/20227,421
Cearley CassiaChief Business Officer07/29/20222,779
Cearley CassiaChief Business Officer08/02/20222,031
Simpson Adam K.Chief Executive Officer07/01/20226,035
MCDADE MARKDirector04/01/2022299,797
Simpson Adam K.Chief Executive Officer03/28/20224,023
RA CAPITAL MANAGEMENT, L.P.Director03/29/202242,271
RA CAPITAL MANAGEMENT, L.P.Director03/28/2022794,611
Cearley CassiaChief Business Officer03/18/202229,515
Cearley CassiaChief Business Officer03/07/2022171,629
Richardson Charles ESVP, Technical Operations02/14/202262,188
Kanesa-thasan NiranjanChief Medical Officer02/02/202252,101
Simpson Adam K.Chief Executive Officer01/26/202290,968
Cearley CassiaChief Business Officer11/15/202118,756
NanoDimension III, L.P.Former 10% Owner08/02/20212,000,010
RA CAPITAL MANAGEMENT, L.P.Director08/02/202139,999,990
Gould Terry PDirector08/02/20212,000,010
ADAMS STREET PARTNERS LLCFormer 10% Owner08/02/20212,000,010
Richardson Charles ESee Remarks07/30/2021416,250
Cearley CassiaChief Business Officer07/30/2021416,250
Veneman Ann MDirector07/30/2021127,500
Qiming U.S. Healthcare Fund II, L.P.Former 10% Owner08/02/20213,320,265
Holtzman DouglasChief Scientific Officer07/30/2021622,500
FIELDS HEIDIDirector07/30/2021131,250
Simpson Adam K.Chief Executive Officer07/30/20211,875,000
Kanesa-thasan NiranjanChief Medical Officer07/30/2021622,500
Kanesa-thasan NiranjanChief Medical Officer08/02/202199,990
Russo Thomas JosephChief Financial Officer07/30/2021487,500
Sanofi10% Owner08/02/20211,000,005
Load More Insider Transactions
FUNDS WITH A POSITION IN ICOSAVAX INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
RA CAPITAL MANAGEMENT, L.P.00.00000%-100.00%Other
PENTWATER CAPITAL MANAGEMENT LP3,000,0000.53%ExitedEvent Driven
BlackRock Inc.2,467,8100.00097%-4.41%Other
VIVO CAPITAL, LLC1,704,5682.2%ExitedOther
PLATINUM INVESTMENT MANAGEMENT LTD1,380,6180.88%ExitedGrowth At A Reasonable Price, Value
WATER ISLAND CAPITAL LLC876,0001.41%ExitedEvent Driven
GEODE CAPITAL MANAGEMENT, LLC709,3220.00117%ExitedOther
TIG ADVISORS, LLC507,1221%ExitedEvent Driven
GABELLI FUNDS LLC254,2570.03%ExitedEvent Driven, Growth, Activists
AQR ARBITRAGE LLC190,2690.12%ExitedEvent Driven
RENAISSANCE TECHNOLOGIES LLC151,2000.00369%ExitedOther
TUDOR INVESTMENT CORP ET AL100,0010.01%ExitedEvent Driven, Other
HARVEST MANAGEMENT LLC79,0001.15%ExitedEvent Driven
ALPS ADVISORS INC35,4340.00439%ExitedOther
D. E. SHAW & CO., INC.23,7150.00033%ExitedOther
BALYASNY ASSET MANAGEMENT L.P.15,3810.00046%ExitedEvent Driven
CHANGE IN SHARES OUTSTANDING FOR ICOSAVAX INC
STOCK BUYBACKS FOR ICOSAVAX INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2023
06/30/2023
11.75%
1Q
09/30/2023
03/31/2023
21.24%
2Q
09/30/2023
12/31/2022
24.98%
3Q
09/30/2023
09/30/2022
25.87%
4Q
09/30/2023
06/30/2022
26.36%
5Q
09/30/2023
03/31/2022
26.98%
6Q
09/30/2023
09/30/2021
88.83%
8Q
Load More

Period of Report: 09/30/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2023
11.75%
1Q
03/31/2023
21.24%
2Q
12/31/2022
24.98%
3Q
09/30/2022
25.87%
4Q
06/30/2022
26.36%
5Q
03/31/2022
26.98%
6Q
09/30/2021
88.83%
8Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ICOSAVAX INC
LOADING...